Key facts
- HealthCode Bio’s last known valuation is $417.9M (May 2022).
- Notable investors include Wuxi Industry Development Group, Cathy Fortune Corporation, Shanghai Huamin Investment.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for HealthCode Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for HealthCode Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About HealthCode Bio
Developer of health assessment and disease diagnostic reagents and microchips, designed for modern biotechnological solutions. The company focuses on the development of human health assessment and disease diagnostic reagents and microchips, offering a macro bioinformatics testing, monitoring, and analysis system based on de novo protein technology, enabling the healthcare industry with biotech production.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2015
- Employees
- 29
- Website
- healthcodon.com/
- Ownership
- Privately Held (backing)
HealthCode Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in HealthCode Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on HealthCode Bio in its N-PORT filings yet. We sweep new filings monthly.